نتائج البحث

المصدر: Sanchez-Magraner, L, Miles, J, Baker, C L, Applebee, C, Lee, D-J, Elsheikh, S, Lashin, S, Withers, K, Watts, A, Parry, R, Edmead, C, Lopez, J I, Mehta, R, Italiano, A, Ward, S G, Parker, P J & Larijani, B 2020, ' High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment ', Cancer Research, vol. 80, no. 19, pp. 4244-4257 . https://doi.org/10.1158/0008-5472.CAN-20-1117Test

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, Lung Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Immune system, Carcinoma, Non-Small-Cell Lung, PD-L1, Fluorescence Resonance Energy Transfer, medicine, Humans, Molecular Targeted Therapy, Carcinoma, Renal Cell, Melanoma, Aged, Cluster of differentiation, biology, business.industry, Reproducibility of Results, Cancer, Immunosuppression, Middle Aged, medicine.disease, Kidney Neoplasms, Immune checkpoint, 3. Good health, Treatment Outcome, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cancer research, biology.protein, Female, business, CD80

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::372c5ebcf055e5084c32083fad16bb71Test
https://doi.org/10.1158/0008-5472.can-20-1117Test

5

A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors

المؤلفون: Joanna Roder, Carlos R. Oliveira, Egbert F. Smit, Mirte Muller, Heinrich Roder, Kim Monkhorst, Anna-Larissa N. Niemeijer, Joachim G.J.V. Aerts, Karlijn Hummelink, Daan P. Hurkmans

المساهمون: Internal medicine, Pulmonary medicine, AII - Cancer immunology, CCA - Cancer biology and immunology, Pulmonary Medicine

المصدر: Clinical Cancer Research, 26(19), 5188-5197. American Association for Cancer Research Inc.
Clinical Cancer Research, 26(19), 5188-5197. AMER ASSOC CANCER RESEARCH
Muller, M, Hummelink, K, Hurkmans, D P, Niemeijer, A-L N, Monkhorst, K, Roder, J, Oliveira, C, Roder, H, Aerts, J G & Smit, E F 2020, ' A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors ', Clinical Cancer Research, vol. 26, no. 19, pp. 5188-5197 . https://doi.org/10.1158/1078-0432.CCR-20-0538Test

مصطلحات موضوعية: Adult, Male, Proteomics, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Immune checkpoint inhibitors, Programmed Cell Death 1 Receptor, B7-H1 Antigen, Machine Learning, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Text mining, SDG 3 - Good Health and Well-being, Carcinoma, Non-Small-Cell Lung, Internal medicine, Biomarkers, Tumor, medicine, Humans, Prospective Studies, Lung cancer, Prospective cohort study, Immune Checkpoint Inhibitors, Aged, Aged, 80 and over, business.industry, Retrospective cohort study, Blood Proteins, Middle Aged, medicine.disease, Progression-Free Survival, Confidence interval, Gene Expression Regulation, Neoplastic, Treatment Outcome, 030104 developmental biology, Docetaxel, 030220 oncology & carcinogenesis, Female, Nivolumab, business, medicine.drug